Why did the share price of AbbVie (NYSE:ABBV) decline despite the Apogee Therapeutics (NASDAQ:APGE) acquisition?

The share price of AbbVie (NYSE:ABBV) declined to $217.79 as the market processed the $10.9 billion all-cash purchase price. Investors reacted to the 60% premium paid for Apogee Therapeutics (NASDAQ:APGE) and the company forecast indicating the transaction will not become accretive to earnings until 2032.

How is Regeneron Pharmaceuticals (NASDAQ:REGN) impacted by the new asset pipeline at AbbVie (NYSE:ABBV)?

Regeneron Pharmaceuticals (NASDAQ:REGN) faces direct future competition as AbbVie (NYSE:ABBV) advances its newly acquired therapy for atopic dermatitis. The acquired drug offers a less frequent dosing schedule, which could challenge the existing market dominance of current therapies that generate billions in annual revenue.

What are the strategic similarities between Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) in the immunology sector?

Both Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) actively acquire clinical-stage biotechnology companies to offset revenue losses from expiring patents. These pharmaceutical corporations utilize large cash reserves to purchase late-stage biologic assets that executives project will drive long-term commercial growth.

What does the $10.9 billion valuation mean for acquisition strategies at Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV)?

The $10.9 billion paid by AbbVie (NYSE:ABBV) indicates that large drugmakers must pay substantial premiums to secure late-stage clinical assets. Competitors like Amgen (NASDAQ:AMGN) face higher capital requirements to execute similar acquisitions within the highly competitive immunology and autoimmune sectors.

Why are companies like Eli Lilly and Company (NYSE:LLY) and AbbVie (NYSE:ABBV) focusing on long-acting biologic therapies?

Eli Lilly and Company (NYSE:LLY) and AbbVie (NYSE:ABBV) target long-acting biologics because extended dosing intervals provide a competitive advantage in patient adherence. Executives project that therapies requiring fewer annual injections will capture significant market share across dermatology and respiratory disease categories.

Image for illustrative purposes only. Not a real photo.

Why dominant pharmaceutical firms are paying billion-dollar premiums for immunology assets

Written by Isaac FrancisPublished Jun 27, 2026, 1:00 AM

AbbVie agreed to acquire Apogee Therapeutics in a $10.9 billion all-cash transaction, paying a 60% premium to secure a late-stage immunology pipeline.
The company will pay $135.11 per share, with executives projecting the deal will not become accretive to adjusted earnings until 2032.
Large pharmaceutical manufacturers face intense capital pressure to acquire unproven, long-acting biologics to offset impending revenue losses from patent expirations.

AbbVie (NYSE:ABBV)

AbbVie executed an agreement to acquire Apogee Therapeutics for $135.11 per share in a $10.9 billion all-cash transaction.

The purchase aims to secure zumilokibart, a late-stage antibody for atopic dermatitis, as the company faces patent expirations for older legacy drugs.

Following the announcement, the share price declined to $217.79.

Executives project the acquisition will become accretive to adjusted diluted earnings per share beginning in 2032.

Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals operates as a direct competitor in the immunology and respiratory disease markets.

The firm jointly developed the atopic dermatitis treatment Dupixent, which generated approximately $11.6 billion in global sales last year.

The company focuses heavily on defending its market share against emerging extended half-life therapies.

Management regularly states the firm will reinvest capital into its proprietary antibody platform to maintain operational scale.

Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson manages a broad portfolio of late-stage immunology assets that compete directly with the newly acquired pipeline.

The firm recently reported quarterly innovative medicine revenues exceeding $13 billion, driven by sales of its core inflammatory disease treatments.

The company utilizes a similar strategy of acquiring clinical-stage biotechnology firms to replenish its portfolio.

Executives project continued targeting of long-acting biologics to offset anticipated revenue declines from impending biosimilar competition.

Amgen (NASDAQ:AMGN)

Amgen manufactures and markets biologic therapies targeting inflammatory and autoimmune conditions.

The company regularly reports quarterly product sales near $7 billion, with immunology representing a core revenue driver.

The firm acquires mid-sized biotechnology competitors to secure new mechanisms of action for complex diseases.

Management states that market pressures require the corporation to aggressively defend its pricing strategies as next-generation injectable therapies enter the treatment landscape.

Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company develops competitive therapies targeting dermatology and gastroenterology markets.

The firm generated over $8 billion in recent quarterly revenue while expanding its commercial presence in the immunology sector.

The company markets treatments that require more frequent patient dosing compared to newly acquired long-acting candidates.

Management notes the company will continue allocating capital toward late-stage acquisitions to secure specialized biologic manufacturing capacity.

The bottom line

The multi-billion-dollar premium paid for late-stage dermatology and asthma assets highlights the intense competition for next-generation biologics.

Pharmaceutical companies are utilizing significant cash reserves to acquire therapies with longer dosing intervals to defend against biosimilar market entries.

Valuations across the sector now heavily depend on the ability to successfully transition these acquired clinical pipelines into profitable commercial products before legacy patents expire.